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Characterizing unmet medical need and the potential
role of new biologic treatment options in patients
with ulcerative colitis and Crohn’s disease:
a systematic review and clinician surveys
Jason P. Gordona,e, Phil C. McEwana,b, Andy Maguirec, Daniel M. Sugruea and Jorge Puellesd
Objectives Comparative outcomes of patients with ulcerative colitis (UC) and Crohn’s disease (CD) prescribed a biologic
therapy are inconclusive. The aim of this research was to characterize the degree of unmet medical need in patients with UC or
CD and to identify the potential role for new therapies.
Methods A systematic literature review was undertaken of studies reporting outcomes associated with the use of existing
biologic therapies in patients with UC or CD, focusing on the nature and rate of treatment failure. To complement the systematic
review, contemporaneous data were obtained from a survey of practising gastroenterologists in the UK and France. Data were
qualitatively combined in a narrative framework to evaluate the degree of unmet medical need among patients with UC or CD.
Results Studies identiﬁed in the systematic review (n=120) were heterogeneous, particularly with respect to the deﬁnitions of
treatment failure; estimates of treatment failure were high but uncertain. On the basis of standardized deﬁnitions, estimates of
treatment failure provided by clinicians (n=102) were high, and they were higher for second-line treatment failure (primary:
≤37%; secondary: ≤41%) compared with ﬁrst-line treatment failure (primary: ≤26%; secondary: ≤ 28%). The majority of the
systematic review and survey data were reﬂective of outcomes with inﬂiximab and adalimumab.
Conclusion High treatment failure rates associated with existing biologics, identiﬁed by the review and clinician surveys, indicate
a need for other biologic treatment options to improve the management and outcomes for people with UC and CD. Outcomes
associated with existing and new biologic treatments should be investigated in head-to-head randomized trials in the context of
their likely uses in clinical practice. Eur J Gastroenterol Hepatol 27:804–812
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
The aim of treatment of ulcerative colitis (UC) and Crohn’s
disease (CD), the two most common forms of inﬂamma-
tory bowel disease (IBD) [1], is achievement of remission
and, once that is achieved, maintaining remission.
Conventional therapies, such as aminosalicylates, corti-
costeroids, general immunosuppressants or antibiotics, are
used to treat the symptoms of active disease [2]. However,
patients unable to receive conventional therapies due to
intolerance, lack of response or ineligibility, or those with
moderate or severe disease, commonly receive biologic
therapy. Available biologic therapies include the anti-
tumour necrosis factor-α (anti-TNFα) agents, inﬂiximab
(IFX), adalimumab (ADA), certolizumab pegol (CTZ) and
golimumab (GOL), and the anti-α4 integrin natalizumab
(NAT) [3–7].
Blockade of TNFα signalling has several limitations;
biologic agents with this mechanism of action (IFX, ADA,
CTZ and GOL) are unable to solely block the immune
system from attacking the body’s own tissue (such as
intestinal tissue in UC and CD) while leaving the rest of the
immune response intact. Consequently, anti-TNFα biolo-
gics may reduce the body’s ability to ﬁght other infections,
leaving UC and CD patients receiving these therapies
susceptible to other diseases and infections [3–6]. For
instance, anti-TNFα biologics have been associated with
the recurrence of tuberculosis in patients with latent
tuberculosis infection, atypical mycobacterial infections
and invasive fungal infections, such as by histoplasmosis,
as well as other opportunistic infections [8,9]. On rare
occasions, blood disorders have been observed with IFX,
ADA and CTZ treatment [3–6], and, although reports of
lymphoma in patients taking IFX, ADA and CTZ are rare,
it does occur more often than in the general population
[10,11].
A biologic with a different mechanism of action may be
more suitable for patients who have experienced primary
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or secondary failure with anti-TNFα biologics. Currently,
NAT is speciﬁcally available for the population of patients
with CD, but not for UC, and is the only non-anti-TNFα
biologic approved by the US Food and Drug
Administration [7]. However, similar to anti-TNFα bio-
logics, NAT does not speciﬁcally and solely target gut
inﬂammation, instead hindering the ability of immune cells
to be recruited to sites of inﬂammation throughout the
body, which may lower the ability of the immune system
to ﬁght infections, increasing the risk for infections in
NAT-treated patients [7]. Vedolizumab, a humanized
IgG1 monoclonal antibody, is also a biologic targeting the
alpha-4 integrin, but it has a new mechanism of action that
leads to the selective inhibition of immune cell recruitment
to the gut [12]; although not currently routinely available,
vedolizumab is under evaluation for use in clinical practice
in the UK [13,14].
The efﬁcacies of available biologic treatments have been
evaluated against placebo in relevant clinical trials [15–
26]; however, the comparative effectiveness of these
treatments, in particular, outcomes observed in clinical
practice outside of the trial setting, is not conclusive.
Empirical studies and meta-analyses on the comparative
effectiveness of existing biologic treatments have indicated
the potential for patient-relevant differences in outcomes,
whereas other studies have concluded that there is no
evidence of clinical superiority among anti-TNFα agents
[27–31]. Consequently, the extent of unmet medical need
among patients who have, or will have, an inadequate
response to, have lost response to, or have intolerance to,
either conventional therapy or existing biologics, is not
established.
The objective of this research was to characterize the
degree of unmet medical need among patients with UC or
CD and to identify the potential role for newer therapeutic
options.
Methods
A systematic literature review and narrative summary of
studies reporting outcomes associated with the use of
existing biologic therapies in patients with UC or CD was
undertaken. To complement the systematic review, con-
temporaneous data were obtained from a survey of prac-
tising gastroenterologists in the UK and France. Data
obtained from the systematic review and surveys were
qualitatively combined in a narrative framework to eval-
uate the degree of unmet medical need (deﬁned by the rate
of treatment failure) and the potential role for new biologic
therapies.
The principle outcomes assessed by the review and
surveys were the rate of treatment failure and the clinician
response to failure during the induction phase (primary
failure) or maintenance phase (secondary failure). Where
possible, failure rates were summarized by type of biologic,
therapy line (ﬁrst or second), timing of treatment failure
from biologic initiation (months) and clinicians’ likely
therapeutic response to treatment failure. Secondary out-
comes assessed in the review were resource use, adverse
events (AEs) and quality of life of patients with UC or CD
treated with a biologic agent; these outcomes and further
details on treatment patterns are reported in full detail in
Supplementary digital content 1, http://links.lww.com/
EJGH/A23.
Systematic literature review
The systematic literature review was conducted in accor-
dance with the PRISMA statement [32], and in accordance
with the methodology described by the Cochrane
Collaboration and the National Institute for Health and
Care Excellence [33,34]. The following databases were
searched to identify relevant studies on biologic agents for
UC and CD: Embase, Medline (through PubMed), the
Cochrane Database of Systematic Reviews, the Cochrane
Central Register of Controlled Trials, and the NHS
Economic Evaluation Database (NHS EED). A search for
human studies in these databases from the inception of
individual databases to the date of the search (9 October
2013) was performed using controlled vocabulary
descriptors and speciﬁc keywords to represent the concept
of UC, CD, IBD and therapeutic use of biologic agents.
The studies of interest were randomized controlled trials,
nonrandomized trials and observational studies.
Bibliographic searches of the identiﬁed systematic reviews
were conducted to identify any potentially relevant study
not identiﬁed in the original search.
Search terms and systematic review methodology,
including inclusion and exclusion criteria, are provided as
Supplemental digital content 2, http://links.lww.com/
EJGH/A24. Searches were limited to articles published in
English and including a human adult population
(≥18 years) with IBD (UC/CD/IBD unknown), treated with
an anti-TNFα agent and reporting data pertinent to clinical
outcomes, treatment patterns, AEs and economic out-
comes. Searches were limited by country of origin, to
characterize clinical practice and degree of unmet need in
countries in which new biologic therapies with different
mechanisms of action will likely become available as
treatment alternatives to conventional treatment options
for UC and CD [12,35]. Search terms identiﬁed studies
from 15 European Union countries [Austria, Belgium,
Denmark, Finland, France, Germany, Greece, Ireland,
Italy, Luxembourg, the Netherlands, Portugal, Spain,
Sweden, UK (England, Wales, Scotland)] and from seven
other countries (Australia, Brazil, Canada, Mexico, New
Zealand, Russia and USA).
After performing the searches, two investigators inde-
pendently reviewed the titles and abstracts of all identiﬁed
citations to generate a list of potentially relevant articles
for further review. Full texts were obtained for the relevant
articles identiﬁed, which were also reviewed independently
by two reviewers using a prespeciﬁed data extraction grid
with a positive inclusion strategy. Discrepancies in the data
extracted were resolved through consensus. Where more
than one publication was identiﬁed describing a single
study, data were compiled into a single entry to avoid
double counting. Only data from full-text publications
were included. Studies included in the evidence synthesis
were those prioritized as relevant to the study objectives,
on the basis of publication year, publication type, country,
disease type, interventions and outcomes assessed.
Reporting of the systematic literature review was qua-
litative (a narrative summary of published studies) and
quantitative (a numerical summary of reported ranges).
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Published rates of primary failure, secondary failure, dose
escalation and switching of biologics were also reported
where available.
Clinician surveys
A cross-sectional survey was conducted to elicit expert
clinical opinion among gastroenterologists practising in a
secondary-care setting in the UK (n= 50) and France
(n=52) in relation to the failure rates seen among patients
treated with existing biologic products and to understand
how these patients were subsequently treated. The aim of
this survey was to inform gaps in the published literature
and clarify uncertainties identiﬁed following the systematic
literature review.
UK and France were chosen as the study countries to
capture current clinical practice with IFX and ADA (the
mainstays of biologic therapy in the UK), and GOL and
CTZ, which are used in clinical practice in France but not
in the UK. Senior-level gastroenterologists, who had
agreed to participate in market research run by Cegedim
Strategic Data (CSD database), were invited to participate;
all gastroenterologists agreeing to participate in this
research completed the questionnaire. To be eligible for
participation, the clinicians had to be a practising gastro-
enterologist treating patients with either CD (n>10) or
UC (n> 5) with a biologic product at the time of the sur-
vey. The ﬁeldwork periods for the UK and France were 27
January–12 February 2014, and 14 February–24 February
2014, respectively.
The gastroenterologists were asked to answer a series of
multiple choice, closed-ended and open-ended questions
related to the study objectives. The questionnaire was
administered as an online survey (see Supplemental digital
content 3, http://links.lww.com/EJGH/A25). Pretesting of
the questionnaire by seven gastroenterologists was under-
taken to validate the survey questions, ensuring that the
survey was reliable and met its objectives; no modiﬁcations
to the survey were suggested. The survey questions pre-
dominantly required a numerical response. A minority of
the questions were in free-text format. Numerical data were
summarized as means and SDs, and number of clinicians
who completed the questionnaire (N); plots are provided
for illustrative purposes, reporting the median and inter-
quartile range of the data. Qualitative responses were
summarized by combining like responses into a common
numerical format (i.e. categorical variable) and producing
associated summary statistics. Analyses were carried out in
Microsoft Excel and Stata version 11 [36,37].
The majority of survey questions elicited data on pri-
mary failure and secondary failure. Survey respondents
were provided with the following working deﬁnitions of
treatment failure, on the basis of the deﬁnitions provided
by Yanai and Hanauer [38]. Primary failure: lack of
improvement in clinical signs and symptoms during
induction therapy, leading to discontinuation of a given
biologic therapy. Reduced response: loss of response dur-
ing maintenance therapy, deﬁned as the occurrence of
disease activity after achieving an appropriate induction
response, without immediate discontinuation of a given
biologic therapy. Secondary failure: loss of response dur-
ing maintenance therapy, deﬁned as recurrence of disease
activity after achieving an appropriate induction response,
leading to discontinuation of a given biologic therapy.
Results
Systematic literature review
Of the 120 full-text publications included for evidence
synthesis (PRISMA diagram presented as Fig. 1; identiﬁed
publications listed within Supplemental digital content 1,
http://links.lww.com/EJGH/A23), 24 were identiﬁed for
UC, 76 for CD, 15 for IBD combined (both UC and CD)
and ﬁve for IBD unspeciﬁed (UC, CD or indeterminate).
Treatment patterns and pathways
Variations in treatment patterns were reported for both
UC and CD. Studies typically reported the use of con-
ventional treatment pathways for IBD (both UC and CD),
including initiation of therapy with corticosteroids, fol-
lowed by the use of biologics in patients who failed cor-
ticosteroid therapy. Among the anti-TNFα agents, the
published literature provided evidence of a preference for
IFX over ADA as ﬁrst-line biologic therapy for both UC
and CD. Failure with an anti-TNFα agent was managed by
dose escalation of the same biologic or switching to
another anti-TNFα agent or corticosteroids. Surgery was
used as an option at any stage to manage therapy failure
and disease progression.
Response rates and treatment failures
The systematic literature review found that primary failure
and secondary failure with ﬁrst-line IFX (the most com-
mon ﬁrst-line anti-TNFα agent) was common in both UC
and CD patients, and that rates of failure with second-line
anti-TNFα agents were also high. However, deﬁnitive
conclusions on differences in the rates of failure between
ﬁrst-line and second-line biologic therapies were difﬁcult
to make, given the wide ranges of reported values and
heterogeneity across studies (Tables 1 and 2). There was
some evidence to suggest that treatment failure (as mea-
sured by the proportion of patients undergoing dose
escalation) was higher at second-line biologic treatment
compared with ﬁrst-line biologic treatment (see Tables S1
and S2, Supplemental digital content 1, http://links.lww.
com/EJGH/A23). This is in line with evidence from several
clinical studies, supporting the conclusion that response to
second-line anti-TNFα agents tends to decrease in patients
exposed to prior anti-TNFα agents [31,57,58].
Adverse events, resource use and quality of life
The literature review also sought to characterize published
data on AEs, resource use and quality of life in patients
with UC/CD who received biologic treatments. These data
are summarized in Supplemental digital content 1, http://
links.lww.com/EJGH/A23 (Tables S5–S10). The most
commonly reported AEs were infections and infusion
reactions. In terms of resource utilization, most of the
studies reported data at an aggregated level for direct
healthcare costs. Secondary failure to an anti-TNFα agent
was associated with an increase in total cost; the cost of
anti-TNFα agents was the highest contributing factor to
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overall costs (see Tables S3–S5, Supplemental digital con-
tent 1, http://links.lww.com/EJGH/A23).
Data gaps and uncertainty in the evidence base
Although a signiﬁcant amount of data was uncovered from
the published literature, it was apparent that there was
signiﬁcant between-study heterogeneity and a number of
evidence gaps (Table 3). Deﬁnitions for primary failure
and secondary failure varied and were not consistently
reported. There was relatively more evidence characteriz-
ing the use and outcomes of IFX therapy, and lesser evi-
dence for ADA, with few studies providing evidence on the
use of other available biologics such as NAT, GOL and
CTZ. Furthermore, there remain gaps in the literature in
the reporting of therapeutic rates of primary failure and
secondary failure, or the response to treatment failure
(such as dose escalation or therapy switching) across
treatments, which need to be characterized to fully ascer-
tain the extent of unmet need in patients with UC and CD.
Clinician survey
The expert opinion of gastroenterologists (respondents) in
the UK (n=50) and France (n= 52) was elicited to clarify
and extend the evidence base identiﬁed in the systematic
literature review.
Respondents from both countries had more experience
in the treatment of CD than in the treatment of UC. The
mean number of patients with CD that a clinician in the
UK reported to have treated with biologic therapy was 70,
versus 34 patients with UC; by comparison, French clin-
icians treated a mean of 44 patients with CD using biologic
therapies, compared with 27 patients with UC. However,
whereas the experience of UK clinicians was restricted to
IFX and ADA, French clinicians had experience in the use
of IFX, ADA, GOL and CTZ.
Clinical practice and unmet need
In the UK context, fewer CD compared with UC patients
were classiﬁed as having severe disease, rather than mod-
erate disease, at onset (57 vs. 69% were classiﬁed as
having severe CD and UC, respectively). However, on
average, it was estimated that CD patients were treated
with a biologic 8 months sooner than UC patients (15 vs.
23 months from disease onset to ﬁrst biologic therapy).
The experience of UK clinicians was restricted to IFX and
ADA, and in this context, clinicians were asked a series of
questions related to treatment failure and response with
ﬁrst-line and second-line biologic therapy with these two
anti-TNFα agents.
In France, the proportion of patients classiﬁed as having
severe disease rather than moderate disease were similar
among UC and CD patients, with more patients
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Fig. 1. The trial ﬂow of the review process (per PRISMA statement [32]). NHS EED, NHS Economic Evaluation Database.
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categorized as severe for both (UC: 58% severe vs. 40%
moderate; CD: 55% severe vs. 44% moderate). However,
consistent with UK clinician experience, it was estimated
that CD patients were treated with a biologic 6 months
sooner than UC patients (12 vs. 18 months on average
from disease onset to administration of ﬁrst-line anti-
TNFα agent). French clinician experience was reported for
IFX, ADA, GOL and CTZ, and in this context, clinicians
were asked a series of questions related to treatment failure
and response with ﬁrst-line and second-line anti-TNFα
agents; clinician experience was predominantly in treatment
with IFX and ADA, with clinicians having limited
experience with GOL and CTZ.
Rate and timing of therapy failure
When asked to estimate treatment failure on the basis of
their own experience, UK clinicians estimated that
18–26% of patients fail and discontinue therapy with a
ﬁrst-line anti-TNFα agent during the induction phase
(primary failure), and that 22–26% lose response and
discontinue that anti-TNFα agent over time – that is, sec-
ondary failure of the ﬁrst-line anti-TNFα agent. Estimates
of treatment failure were even higher for second-line
treatment with an anti-TNFα agent: 28–37% of patients
fail and discontinue treatment during the induction phase,
and 31–41% lose response and discontinue their second-
line anti-TNFα agent treatment over time (Fig. 2). Among
patients who lost response, it was estimated that 68–77%
of patients discontinued treatment by the end of the ﬁrst
year, and 82–90% of patients discontinued treatment by
the end of the second year of treatment due to loss of
response.
French clinicians estimated that up to 26% of patients
failed and discontinued ﬁrst-line biologic therapy during
the induction phase, and up to 28% lose response and
discontinue therapy with an anti-TNFα agent over time.
Estimates of treatment failure were even higher with
second-line anti-TNFα agents, where it was estimated that
up to 29% of patients failed and discontinued treatment
during the induction phase, and up to 40% lose response
and discontinue an anti-TNFα agent over time (Fig. 3).
Among patients who lose response and discontinue bio-
logic treatment, it was estimated that 45–60% discontinue
treatment by the end of their ﬁrst year of treatment. By the
end of the third year of treatment, 73–87% of patients
discontinue treatment due to loss of response.
Clinician response to treatment failure
UK clinicians estimated that in patients with ﬁrst-line
treatment failure who showed signs of a reduced response,
their response would be to add another (nonbiologic)
treatment, such as corticosteroids, in around 25% of cases,
increase the dose of the existing biologic therapy in
21–24% of cases, increase the administration frequency in
17–25% of cases, and offer surgery as a treatment option
in 20–22% of cases. When treatment alternatives in
patients failing ﬁrst-line biologic therapy were restricted to
surgery or a switch to a second-line biologic, UK clinicians
estimated that among UC patients failing IFX as a ﬁrst-line
anti-TNFα agent, around 50% would switch to ADA as a
second-line anti-TNFα agent and the other 50% would
pursue surgery as a treatment option. Similarly among
ADA failures, around 50% would switch to IFX as a
second-line anti-TNFα agent and 50% would pursue sur-
gery. Among CD patients failing IFX, clinicians estimated
that around 70% would switch to ADA as a second-line
anti-TNFα agent and the other 30% would pursue surgery
as a treatment option. For ADA failures, around 50%
would switch to IFX as a second-line anti-TNFα agent and
Table 1. Range of reported treatment failure rates in ulcerative colitis
identiﬁed in the systematic literature review
Treatment Parameter Range References
Reported rates of treatment failure following therapy with ﬁrst-line anti-TNFα agent
Inﬂiximab Primary failure 19–58% Alzaﬁri et al. [39]
Herrlinger et al.
[40]
Secondary failure (loss of
response)
17–22% Herrlinger et al.
[40]
Gies et al. [41]
Dose escalation 18.9–40% Oussalah et al.
[42]
Gies et al. [41]
Switching to second-line
anti-TNFαa
7.7–16.7% Alzaﬁri et al. [39]
Herrlinger et al.
[40]
Reported rates of treatment failure following therapy with second-line anti-TNFα
agent
Inﬂiximab Primary failure 52%b Ho et al. [43]
Loss of response NR NR
Dose escalation NR NR
Switching to third-line anti-
TNFα agent
NR NR
Adalimumab Primary failure NR NR
Loss of response 43%b Taxonera et al.
[44]
Dose escalation 35–46% Aﬁf et al. [45]
Oussalah et al.
[46]
Switching to third-line anti-
TNFα agenta
NR NR
NR, not reported; TNFα, tumour necrosis factor-α.
aAny anti-TNFα agent.
bReported in one study only.
Table 2. Range of reported treatment failure rates in Crohn’s disease
identiﬁed in the systematic literature review
Treatment Parameter Range References
Reported rates of treatment failure following therapy with ﬁrst-line anti-TNFα agent
Inﬂiximab Primary failure 7–60% Lees et al. [47]
Katz et al. [48]
Secondary failure (loss of
response)
4–21.2% Lees et al. [47]
Chaparro et al. [49]
Dose escalation 5–27.4% Chaparro et al. [49]
CHARM Trial:
Colombel et al. [16]
Switching to second-line
anti-TNFα agenta
2–26.5% Oussalah et al. [50]
Chaparro et al. [49]
Reported rates of treatment failure following therapy with second-line anti-TNFα
agent
Adalimumab Primary failure 8–32% Russo et al. [51]
Ho et al. [52]
Loss of response 3–20.8% Swoger et al. [53]
Peyrin-Biroulet et al.
[54]
Dose escalation 14–72% CARE Trial: Louis et al.
[55]




NR, not reported; TNFα, tumour necrosis factor-α.
aAny anti-TNFα agent.
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50% would pursue surgery. French clinicians estimated
that among patients with ﬁrst-line treatment failure or a
reduced response, around 18–39% would receive an
additional nonbiologic treatment, such as corticosteroids,
around 12–33% would be administered an increased dose
of the existing anti-TNFα agent, administration frequency
would be increased in around 9–27% of patients and
surgery would be offered to around 7–23% of patients.
When treatment alternatives in patients failing ﬁrst-line
biologic therapy were restricted to surgery or a switch to a
second-line anti-TNFα agent, it was estimated that among
UC patients, around 20% would switch to surgery from




Type of IBD Yes No
Disease duration Yes No
Disease severity Yes No
Intervention Yes No
Concomitant medications Yes No
Treatment history Yes No
Occurrence of primary failure, occurrence of secondary failure, occurrence of intolerance, occurrence of dose
escalation, occurrence of switching, surgery as proxy measure of failure of anti-TNFα agents
Not consistently described Yes
Clinical outcomes: deﬁnitions for response/remission, response rate, remission rate, number of nonresponders Yes No
Details of surgery: number of patients undergoing surgery, type of surgery Yes No
AEs Yes No
Costs and resource use Yes No
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Fig. 2. Treatment failure during anti-TNFα therapy as estimated by UK
clinicians. Estimates of treatment failure are consistently lower for ﬁrst-line
biologic therapy (black boxes) compared with second-line biologic therapy
(grey boxes) in (a) UC and (b) CD, on the basis of the experience of UK
gastroenterologists. Median line with box of 25th/75th percentiles and upper/
lower adjacent values; while reading the ﬁgure, please observe that each
category on the x-axis is assigned two boxes. ADA, adalimumab; anti-TNFα,
anti-tumour necrosis factor-α; CD, Crohn’s disease; IFX, inﬂiximab; PF, pri-
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Fig. 3. Treatment failure during anti-TNFα therapy as estimated by French
clinicians. Estimates of treatment failure are consistently lower for ﬁrst-line
biologic therapy (black boxes) compared with second-line biologic therapy
(grey boxes) in (a) UC and (b) CD, on the basis of the experience of French
gastroenterologists. Median line with box of 25th/75th percentiles and upper/
lower adjacent values; while reading the ﬁgure please observe that each
category on the x-axis is assigned two boxes. ADA, adalimumab; anti-TNFα,
anti-tumour necrosis factor-α; CD, Crohn’s disease; IFX, inﬂiximab; PF, pri-
mary failure; SF, secondary failure; UC, ulcerative colitis.
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biologic therapy (IFX/ADA/CTZ) and 77%would switch
between IFX and ADA (i.e. IFX to ADA or ADA to IFX).
Among CD patients failing a ﬁrst-line anti-TNFα agent,
15% would switch to surgery from IFX/ADA, 26% would
switch from CTZ to surgery and 80% would switch
between IFX and ADA; clinicians estimated that there was
limited switching to GOL or CTZ.
Discussion
The impact of UC and CD on the quality of life of patients
and on medical expenditure is well understood [59], as is
the need for effective treatment options [60]. The efﬁcacy
of conventional treatments and biologic therapies used to
manage cases of UC and CD has been explored in a
number of clinical trials [15–26,61–63]. Meta-analyses
and retrospective analyses of patients receiving the avail-
able biologic therapies suggest that their comparative
effectiveness is similar, whereas other studies point toward
differences between the treatments in terms of patient-
relevant outcomes [27–31]. The current literature, there-
fore, does not allow deﬁnitive conclusions to be drawn
with regard to the comparative outcomes of patients
treated with currently available biologic therapies in clin-
ical practice. This research aimed to characterize treatment
patterns and outcomes of patients with UC and CD and
therein characterize the degree of unmet medical need
among patients with these conditions.
Studies identiﬁed in the systematic review reported high
rates treatment failure – around 7–60% primary failure
and 4–43% secondary failure – which were highly vari-
able. Heterogeneity between studies with regard to deﬁ-
nitions of treatment failure, study sample sizes, study
designs and follow-up periods thwarted a robust quanti-
tative synthesis of estimates of treatment failure across
studies. The narrative summary of the literature that we
report is useful in conﬁrming a general sense of high unmet
need among patients with UC and CD; the wide range of
reported values for treatment failure in the literature con-
ﬁrms the inconclusive nature of the outcomes of treating
patients with existing biologics.
The output of the systematic review also conﬁrmed that
there is a paucity of data describing patterns and outcomes
of treatment for UC and CD in several important respects,
particularly in estimates of treatment failure by type of
biologic therapy and disease. Outcomes for patients
receiving ADA, GOL or CTZ, as well as data character-
izing the time to secondary failure, were not well reported
in the published literature.
Similarly to the ﬁndings from the systematic literature
review, surveyed clinicians estimated that a signiﬁcant
number of patients show failure with existing biologic
therapies during the induction phase (up to 37%) and the
maintenance phase (up to 41%) of treatment. The survey
data provided additional granularity around estimates of
treatment failure. The estimated rates of primary and
secondary failure were high for ﬁrst-line and second-line
therapies, with higher rates of treatment failure observed
among patients switching between available biologic
therapies.
The reviewed literature and estimates of treatment
failure obtained from clinicians treating patients with
biologics in current clinical practice demonstrate that there
is signiﬁcant unmet need among patients with UC and CD.
In the signiﬁcant number of patients who cannot tolerate
or who fail their ﬁrst-prescribed biologic treatment, sub-
sequent pharmacological treatment choices are restricted
to the biologic therapies currently available. Data from this
study suggest that the outcome for patients who cycle
between existing biologic treatment options with similar
mechanisms of action (i.e. IFX, ADA, GOL, CTZ) is likely
to be suboptimal in around 21–41% of cases.
The ﬁndings of the literature review and surveys were
generally consistent. For ﬁrst-line treatment failures, sur-
vey estimates were generally within the ranges reported in
the published literature, with the exception of secondary
failure in IFX-treated patients, where the surveys estimated
slightly higher proportions of treatment failure for both
UC and CD. Survey estimates were also broadly consistent
with observations from a real-world IBD audit, an ongoing
nationwide audit of individual patient care and provision
concerning the organization of IBD services in the UK [64].
The audit has previously reported a primary failure rate of
14.5% among UC patients treated with anti-TNFα agents
(on the basis of a reported primary response of 85.5%).
This is comparable to the primary failure rates identiﬁed
by the survey of UK clinicians, which were 26 and 19% for
patients treated with IFX and ADA, respectively. Similarly,
for CD, a primary failure rate of 12.4% was reported by
the IBD audit (on the basis of an overall response of
87.6%), which compares to the primary failure rates of 18
and 20% estimated for IFX and ADA, respectively, by the
UK clinician survey. In both cases, the IBD audit reported
signiﬁcantly lower primary failure rates compared with
clinician survey results. However, subsequent iterations of
the audit reported that 62% of adult patients treated with
anti-TNFα agents enter remission: an implied failure rate
of 38% [64]. These audit data underscore the degree of
unmet need identiﬁed by the systematic review and sur-
veys, and the potential role of new therapeutic options
with an alternative mechanism of action.
A secondary objective of the systematic literature review
was to extract and qualitatively assess the evidence for
additional treatment outcomes, including costs, AEs and
quality of life. The details of and a brief narrative review of
the literature for these outcomes are provided in
Supplemental digital content 1, http://links.lww.com/
EJGH/A23.
Conclusion
This study underscores the apparent need for newer bio-
logic treatments with novel mechanisms of action that may
offer greater therapeutic value to patients with UC or CD
failing existing biologic therapies. Further evidence is
warranted from both placebo-controlled trials and head-
to-head comparisons of current anti-TNFα agents versus
new therapies to understand the consequences of switching
to a biologic with a novel therapeutic target and
mechanism of action.
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